[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-mild\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-mild":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,77,102,129,151,173,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100572639","fmri-neurofeedback-with-matter-neuroscience-app-100572639",false,"NCT06735885","fMRI Neurofeedback With Matter Neuroscience App","Stanford-Matter Neuroscience High-Resolution fMRI Advanced Neurofeedback Feasibility Trial (fMRI Neurofeedback) Medical","Inclusion Criteria:\n\n1. Male or Female, between the ages of 18 and 80 at the time of screening.\n2. Primary diagnosis of nonpsychotic major depressive disorder (MDD) without a history of psychotic features.\n3. Score on the MADRS scale between 15-25\n4. Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires \u002F follow instructions during fMRI. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.\n5. Must possess an iPhone with the latest iOS version compatible with the app or must be willing to use a loaner iPhone from the study if available.\n6. Has had at least one lifetime antidepressant treatment failure (ATHF)\n7. The dose of the primary antidepressant medication (if applicable) must be stable for 4 weeks prior to baseline, and participants must agree to continue at this dose throughout the study period.\n8. In good general health, as evidenced by medical history and determined by study physician\n9. For women of reproductive potential: agree to the use of highly effective contraception during study participation.\n10. Adequate visual acuity (with or without corrective lenses) to view study materials while in the MRI.\n11. Agreement to adhere to Lifestyle Considerations throughout study duration.\n\nExclusion Criteria:\n\n1. Contraindication to MRI (ferromagnetic metal in their body)\n2. Severe claustrophobia\n3. Women that are pregnant or breastfeeding or with a positive urine pregnancy test at participation, or who are planning to become pregnant during the study period.\n4. Primary psychiatric condition other than MDD requiring treatment except stable comorbid anxiety disorder\n5. History of or current psychotic disorder, schizophrenia, psychosis, bipolar disorder, or severe borderline personality disorder.\n6. Diagnosis of intellectual disability, autism spectrum disorder, or other neurodevelopmental disorder.\n7. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n8. Urine screening test positive for recent use of recreational drugs except for marijuana..\n9. Considered at significant risk for suicide during the course of the study.\n10. Recent (within 4 weeks of any clinical effect) or concurrent use of rapid acting antidepressant agent (i.e., a course of ECT or TMS). Excluding ketamine.\n11. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma as determined by the PD.\n12. Untreated or insufficiently treated endocrine or metabolic disorder.\n13. Any other condition deemed by the PD to interfere with the study or increase risk to the participant\n14. Alexithymia as determined by the Toronto Alexithymia Scale\n15. Treatment with an investigational drug or other intervention within the study period.\n16. Not currently in a major depressive episode as defined by the MINI.\n17. More than 5 lifetime adequate antidepressant medication failures (ATHF).","ALL","18 Years","80 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.",[27,28,29],"Depression Mild","Depression","Depression Moderate","RECRUITING","2026-05-20",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":34},"2025-08-12",{"date":38,"type":21},"2028-06-15",{"name":40,"class":41},"Stanford University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100611163","effects-of-personalized-digital-reminiscence-therapy-on-patients-with-neurocognitive-disorders-100611163","NCT07237009","Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders","Effects of Personalized Reminiscence Sessions Delivered by a Digital Conversational Agent to Patients With Neurocognitive Disorders","Inclusion Criteria:\n\n* Men and women over 60 years of age.\n* DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.\n* Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28.\n* Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both\n* Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.\n* Having voluntarily and informedly agreed to participate in the study (signed written consent).\n* Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).\n* Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.\n* Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.\n* Subjects covered by a social security scheme.\n\nExclusion Criteria:\n\n* Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.\n* Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder).\n* Major hearing or visual impairments.\n* History of premorbid intellectual disability.\n* Patients under guardianship, conservatorship, or legal protection.\n* Patients who have already used the Lilia app\n* Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.\n* Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.","60 Years",{"count":52,"type":21},80,"OBSERVATIONAL","This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.\n\nThe researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.\n\nThe study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.\n\nParticipants will:\n\n* Use the reminiscence app for 25 days for 10-15 minutes.\n* Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group.\n* Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).",[56,57,27,58,59],"Neurocognitive Disorders, Mild","Cognitive Impairment, Mild","Apathy","Apathy in Dementia",[61,62,58,63,64,65],"Mild Cognitive Impairment","Dementia","Mild Depression","Digital Reminiscence therapy","personalized Reminiscence therapy","2026-03-06",{"date":68,"type":34},"2026-03-09",{"date":70,"type":34},"2025-10-14",{"date":72,"type":21},"2026-12",{"name":74,"class":75},"KompanionCare SAS","INDUSTRY",5,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100523123","treating-major-depression-with-yoga-mono-therapy-100523123","NCT06091527","Treating Major Depression With Yoga Mono-therapy","Treating Major Depression With Yoga Mono-therapy: 12-Week Randomized Controlled Trial","Inclusion criteria:\n\n* 18 years of age or older\n* Able to give voluntary, informed consent\n* English-speaking\n* Diagnosis of clinical depression\n\nExclusion criteria:\n\n* Current use of antidepressant medication\n* Current engagement in psychotherapy\n* Current pregnancy\n* Significant medical issues interfering with yoga practice",{"count":85,"type":21},180,[24],"The goal of this single-center, single-blind, randomized, controlled, parallel group, interventional trial is to evaluate antidepressant efficacy of yoga monotherapy of 12-weeks duration in 180 adults meeting diagnostic criteria for mild-to-moderate major depression at the Zuckerberg San Francisco General Hospital. Researchers will compare the yoga interventions to an education control intervention on holistic healthcare.",[27,29],[90,91,92],"yoga","ayurveda","depression","2025-11-04",{"date":95,"type":34},"2025-11-06",{"date":97,"type":34},"2024-10-25",{"date":99,"type":21},"2026-06",{"name":101,"class":41},"University of California, San Francisco",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":17,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100537143","telehealth-behavioral-activation-for-teens-100537143","NCT06273995","Telehealth Behavioral Activation for Teens","Inclusion Criteria:\n\n1. Participants must be enrolled in the Texas Youth Depression Suicide Research Network (TX-YDSRN) Registry Study;\n2. Be between the ages of 12- 18 or currently enrolled in high school;\n3. Have a caregiver that is willing to participate in the program;\n4. Be able to commit to weekly sessions for eight weeks;\n5. Be currently experiencing depressive symptoms;\n6. Be able to participate in telehealth services within the state of Texas;\n7. Be willing to provide consent\u002Fassent (parents\u002Flegally authorized representative (LAR)\u002Fguardian or young adult participant, aged 18 or older, must be willing to provide consent; youth, aged 12-17, must be willing to provide assent);\n8. Be able to read, write and speak English or Spanish sufficiently to understand the study procedures and provide written informed consent to participate in the study;\n9. Be willing to dedicate appropriate time to complete scheduled study assessment and measures and attend intervention sessions (both parent\u002FLAR\u002Fguardian and youth)\n10. Be able to provide a reliable means of contact.\n\nExclusion Criteria:\n\n1. Have an acute medical or psychological condition(s) that that would, in the judgment of the study medical clinician, make participation difficult or unsafe;\n2. Have an acute medical or psychological condition(s) that would result in an inability to accurately complete study requirements (e.g., neurological conditions or significant neurodevelopmental concerns);\n3. Have active psychotic or manic symptoms resulting in altered mental status and inability to provide assent or requiring immediate attention and\u002For higher level of intervention;\n4. Have a parent\u002FLAR\u002Fguardian who is deemed cognitively unable to provide consent (if youth participant, aged 12-17).","12 Years",{"count":110,"type":21},250,[24],"Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms. Research has shown that behavioral activation is an effective intervention for depressed youth. Additionally, it has been shown as a promising intervention that can be conducted in a brief, virtual format and can be effectively implemented by both trained clinicians and trained, non-licensed interventionists. This project will provide Behavioral Activation for youth (12-17) experiencing depression or suicidal ideation who are currently enrolled in the Youth Depression Suicide Network study in Texas.",[28,114,115,27,29,116],"Suicide and Self-harm","Depression in Adolescence","Depression Severe",[118,92,119],"behavioral activation","adolescents","2025-07-18",{"date":122,"type":34},"2025-07-20",{"date":124,"type":34},"2024-03-01",{"date":126,"type":21},"2029-12-01",{"name":128,"class":41},"Baylor College of Medicine",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":42},"100578331","kintsugi-voice-device-pivotal-study-100578331","NCT06809907","Kintsugi Voice Device Pivotal Study","Kintsugi Voice Device SCID-5 Pivotal Study","Inclusion Criteria:\n\nAge \\>22 at the time of informed consent Self-reported disruption to activities of daily living (e.g. missed scheduled healthcare appointments, unable to concentrate on tasks like reading, working, or completing daily activities, or difficult completing activities such as exercise, diet, or recreation) Access to a laptop, smartphone, tablet, or other device with a functioning microphone and access to the Internet Stated willingness to be video and audio recorded as part of the study Stated willingness to comply with all study procedures and availability for the duration of the study Functional English capacity in the home environment Availability for the duration of the study Resides in the United States at the time of consent and during completion of study\n\n\\-\n\nExclusion Criteria:\n\n* Participants with at least one of the following conditions will be excluded:\n\nAny impairment that impacts their ability to speak and\u002For use a computer to complete online surveys and\u002For a virtual clinician assessment (E.g., visual impairment, motor impairment, and\u002For hearing impairment) Any lifetime history of neurological disease that impacts their ability to speak and\u002For use a computer to complete online surveys and\u002For a virtual clinician assessment (E.g., Central Nervous System disorders, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and\u002For Parkinson's Disease) Any lifetime history of Stroke, cognitive defect (E.g., dementia or Alzheimer's disease), and\u002For Traumatic Brain Injury Presence of voice disorders that impacts their ability to speak (E.g., acute or chronic laryngitis, vocal cord paresis or paralysis, or spasmodic dysphonia) Past or active heavy smokers (an average of \\>20 cigarettes per day) Subjects who have previously participated in any Kintsugi-sponsored study",true,"22 Years",{"count":139,"type":21},1000,"A prospective, single arm, non-randomized, pivotal clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made by a clinician using the Structured Clinical Interview for DSM-5 (SCID-5-RV) for up to 1000 English speaking adult patients ages 22 and older living in the United States. Recruitment will occur for 1 year and participation will be for up to 2 weeks",[28,29,116,27],"2025-04-28",{"date":144,"type":34},"2025-04-30",{"date":146,"type":34},"2025-03-27",{"date":148,"type":21},"2025-11",{"name":150,"class":75},"Kintsugi Mindful Wellness, Inc.",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":42},"100557419","icbt-for-seniors-with-depression-in-primary-care-100557419","NCT06537869","iCBT for Seniors With Depression in Primary Care","The New Internet Generation: iCBT Treatment for Seniors With Mild-moderate Depression - a Pragmatic Randomised Controlled Trial in the Primary Care Context","Inclusion Criteria:\n\n* All patients \\>65, attending PCCs engaged in the trial, with mood as well as somatic complaints will be asked about depressive symptoms during the last 2 weeks by NICE guidelines for depression.\n* All patients diagnosed with minor\u002Fmajor depression and not belonging to exclusion criteria and willing to take part in the trial will be diagnosed via the Mini International Neuropsychiatric Interview (M.I.N.I.) by a psychologist\u002Fspecially trained nurse and have a General Practitioner (GP) somatic consultation\n\nExclusion Criteria:\n\nPatients diagnosed with:\n\n* severe depression\n* prior suicide attempt or currently at medium to high risk of suicide (MADRS-S question 9\\>3 points or MINI suicide \\>9)\n* bipolar disorder\n* psychosis\n* addiction\n* cognitive impairment\n* not speaking or understanding Swedish.","65 Years",{"count":160,"type":21},390,[24],"This clinical trial aims to evaluate the potential benefits of internet cognitive behavioural therapy (iCBT) for elderly patients with mild\u002Fmoderate depression and compare its effectiveness with the current treatment as usual (TAU) at primary care centres (PCCs).\n\nThe specific aims are to study if:\n\niCBT is as effective as TAU in reducing depressive symptoms iCBT is as effective as TAU in increasing quality of life iCBT is as effective as TAU in increasing the function in patients \\>65 years and older with mild\u002Fmoderate depression attending primary care, with the perspective of 36 months.\n\nParticipants will:\n\nWork with the iCBT program (10-12 weeks) or become TAU at their PCCs. Followed-up at 3, 6, 12, 24 and 36 months of their symptoms, quality of life and function.",[27,29],"2025-03-31",{"date":166,"type":34},"2025-04-01",{"date":168,"type":34},"2024-09-01",{"date":170,"type":21},"2029-06",{"name":172,"class":41},"Göteborg University",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":42},"100551195","a-pilot-study-comparing-the-efficacy-of-traditional-buddhist-mindfulness-training-versus-secular-mindfulness-based-cognitive-therapy-for-patients-having-residual-depressive-symptoms-100551195","NCT06456931","A Pilot Study Comparing the Efficacy of Traditional Buddhist Mindfulness Training Versus Secular Mindfulness-based Cognitive Therapy for Patients Having Residual Depressive Symptoms","Comparing the Efficacy of Traditional Buddhist Mindfulness Training Versus Secular Mindfulness-based Cognitive Therapy for Residual Depressive Symptoms in Patients With Depressive Disorders: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 or above\n* Buddhist faith (Only Buddhists are selected as one of the interventions involves Buddhist teachings, and any recruited participant has a probability of being enrolled in the Buddhist mindfulness intervention)\n* A history of one or more episodes of moderate or severe depression\n* Currently having BDI-II score \\> 13, i.e., mild to moderate depressive symptoms\n\nExclusion Criteria:\n\n* Currently having a severe depressive episode, according to the Composite International Diagnostic Interview (CIDI) Sinhalese version\n* Currently having moderate to severe suicidal ideation (according to CIDI)\n* Recent changes in antidepressant medication\n* Unable to understand and communicate in Sinhalese",{"count":181,"type":21},60,[24],"This interventional study is conducted with the goal of comparing the efficacy of traditional Buddhist mindfulness training versus secular mindfulness based cognitive therapy among patients with depressive disorders. We are also interested in studying how these interventions compare in terms of preventing further relapses of depression. Additionally, this study aims to identify factors that influence the efficacy of this intervention, such as self-report mindfulness, self-compassion, and religiosity.",[29,27],[186,92,187],"mindfulness","religiosity","2024-06-07",{"date":190,"type":34},"2024-06-13",{"date":192,"type":34},"2024-04-01",{"date":194,"type":21},"2025-10-31",{"name":196,"class":41},"Anuradha Baminiwatta",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100499818","integrated-depression-care-100499818","NCT05788198","Integrated Depression Care","Integrated Depression Care Project","IDECA","Inclusion Criteria:\n\n* persons between 18-65\n* presenting to the general practitioner's office\n* with depressive symtomatology\n\nExclusion Criteria:\n\n* Severe depression warranting direct referral to specialized services\n\nInclusion criteria are kept broad on purpose as it's one of the research questions to define for which patients the intervention (namely the case management) is appropriate.",{"count":206,"type":21},150,[24],"The Integrated DEpression CAre (IDECA) Programme is a multi-faceted intervention strategy aiming to improve guideline adherence and shared care practices for depression management in both providers and patients, as measured through a set of process and clinical outcome indicators (primary outcome measure).",[27,29,116],"2024-06-05",{"date":212,"type":34},"2024-06-06",{"date":214,"type":34},"2023-04-25",{"date":216,"type":21},"2024-09-30",{"name":218,"class":41},"University Ghent",2]